Open Access

BIOGRAPHICAL

H. Magdelénat, J. Rouessé
Oncologie, Vol.21, No.1, pp. 1-2, 2019, DOI:10.3166/onco-2019-0022
Abstract This article has no abstract. More >

View

909

Download

1063

Open Access

EDITORIAL

A. Lesur, F. Guillemin
Oncologie, Vol.21, No.1, pp. 3-4, 2019, DOI:10.3166/onco-2019-0032
Abstract This article has no abstract. More >

View

919

Download

725

Open Access

ARTICLE

S. Dejust
Oncologie, Vol.21, No.1, pp. 5-10, 2019, DOI:10.3166/onco-2019-0031
Abstract Axillary evaluation is a major step in the initial staging of breast cancer. Ultrasound guided biopsy is currently recommended in first-line. MRI and 18FDG PET/CT are useful in axillary lymph node evaluation. Imaging sensitivities and specificities are globally identical and their combination allows obtaining the best performances. Currently, sentinel node technique is essential in case of T1-T2 N0 mammary tumors and in case of suspected lymph node adenopathy with negative cytopuncture or microbiopsy.


Résumé
L’exploration préthérapeutique axillaire est une étape majeure du bilan initial du cancer du sein. L’échographie associée à un prélèvement est actuellement recommandée en première More >

View

997

Download

1296

Open Access

ARTICLE

J. Boudier, G. Oldrini, C. Barlier, A. Lesur
Oncologie, Vol.21, No.1, pp. 11-16, 2019, DOI:10.3166/onco-2019-0034
Abstract When a breast cancer is diagnosed, the quality of the evaluation before treatment is essential to guide the therapeutic decision. The staging axillary is necessary because it estimates the regional extension of the disease, which makes it a paramount prognosis factor. Some different preoperative medical imaging can reveal metastasis axillary nodes. However, the axillary ultrasound remains the reference imaging and it also leads the biopsies too. Since theACOSOG-Z0011 trial, we are facing a therapeutic deescalation in the axillary surgery. According to recent results, we can note that the position of the axillary imaging is more… More >

View

944

Download

890

Open Access

ARTICLE

G. Oldrini, P. Henrot, F. Marchal
Oncologie, Vol.21, No.1, pp. 17-21, 2019, DOI:10.3166/onco-2019-0033
Abstract Breast cancer is the first female cancer in France and its early detection is essential. Breast MRI is an element of choice in its diagnosis but it has high direct and indirect costs because of its duration which slows down its wider use. Given its elements, the use of an abbreviated protocol develops to overcome these disadvantages. Early literature data suggests that this faster examination also allows for a shorter interpretation time. In addition, the sensitivity and specificity of the examination are not inferior to that of the complete protocol. This article explains the new… More >

View

1081

Download

863

Open Access

ARTICLE

F. Guillemin, F. Marchal, M. Geffroy
Oncologie, Vol.21, No.1, pp. 22-28, 2019, DOI:10.3166/onco-2019-0028
Abstract Purpose: Assessment of a second surgical conservative treatment (T) [N = 41] compared to total mastectomy (M) [N = 93] for ipsilateral breast tumor recurrence after initial breast conserving surgery in a retrospective study of 134 patients. Results: Five years global survival was 82.5% in each group. No statistical difference for the specific survival and survival without metastasis. The 5 years local control was 92.9% in group M and 66.2% in group T (RR = 4.48). Lymphovascular invasion (LVI), multifocal tumors, and clinical symptoms of the recurrence are pejorative factors for survival. Over the 134 patients, 25… More >

View

1006

Download

719

Open Access

ARTICLE

V. Massard, A. Harlé, L. Uwer, J.-L. Merlin
Oncologie, Vol.21, No.1, pp. 29-32, 2019, DOI:10.3166/onco-2019-0027
Abstract Acquired endocrine resistance remains one of the main obstacles in the treatment of estrogen receptor (ER) positive, HER2 negative advanced breast cancer. Recently, activating ESR1 gene mutations affecting the ligand-binding domain have been identified as a key mechanism in aromatase inhibitor (AI) resistance. These mutations can be detected on histological samples or circulating tumour DNA, using PCRbased assays or next-generation sequencing. They induce a constitutive activation of ER, leading to acquired resistance to AI; tamoxifen, fulvestrant and targeted therapies against mTOR or CDK4/6 retain their efficacy. The use of monitoring ESR1 mutations in clinical practice is… More >

View

996

Download

1002

Open Access

ARTICLE

A. de Nonneville, A. Gonçalves
Oncologie, Vol.21, No.1, pp. 33-39, 2019, DOI:10.3166/onco-2019-0039
Abstract Triple-negative breast cancer (TNBC), defined by the lack of expression of hormone receptors and HER2 (Human Epidermal growth factor Receptor-2), accounts for 15–20% of breast cancers. However, this definition, which is essentially negative, masks the large biological heterogeneity of this subtype. While chemotherapy is the main established systemic treatment in both early and advanced stages of the disease, the progressive understanding of the molecular components involved in the pathogenesis of TNBC allows innovative therapeutic perspectives. The objective of this review is to describe these potential targets and to explore current and future treatments that will… More >

View

1275

Download

1351

Open Access

ARTICLE

V. Allouchery, L. Augusto, F. Clatot
Oncologie, Vol.21, No.1, pp. 40-48, 2019, DOI:10.3166/onco-2019-0035
Abstract It has been known for a long time that circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA) can be detected. However, only recent technical advances allowed evaluating the interest of CTC and ctDNA in breast cancer. In both early and metastatic breast cancers, CTC detection is a recognized factor for poor outcome. Nevertheless, CTC detection does not impact cancer management yet. The use of ctDNA in daily practice will require validation by prospective data. But ctDNA seems particularly promising both for residual disease evaluation and identification of tumor clones harbouring mutations (PI3KC, ESR1)… More >

View

1068

Download

809

Open Access

EDITORIAL

D. Grazziotin-Soares, J.-P. Lotz
Oncologie, Vol.21, No.1, pp. 49-51, 2019, DOI:10.3166/onco-2019-0037
Abstract This article has no abstract. More >

View

959

Download

803

Open Access

ARTICLE

T. Pudlarz, N. Naoun, G. Beinse, D. Grazziotin-Soares, J.-P. Lot
Oncologie, Vol.21, No.1, pp. 53-68, 2019, DOI:10.3166/onco-2019-0036
Abstract In this special issue of Oncology, we have summarized the most relevant topics that were presented at the American Association for Cancer Research (AACR) meeting. Our purpose here is to give the readers a concise report of the presentations that warrant particular attention. This year 2019 in Atlanta, the AACR Annual Meeting program covered the latest discoveries across the spectrum of cancer research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions… More >

View

1020

Download

939

Open Access

ARTICLE

D. Grazziotin-Soares, J.-P. Lotz
Oncologie, Vol.21, No.1, pp. 69-72, 2019, DOI:10.3166/onco-2019-0030
Abstract Several studies have shown an association between Epstein-Barr virus (EBV) infection and some human cancers such as a subgroup of gastric carcinomas. The oncogenic potential of EBV has been widely explored but the exact processes conducting carcinogenesis are not yet fully understood. EBV-encoded viral proteins are known to deregulate the DNA damage response (DDR) signaling pathways. DDR inactivation leads to genomic instability and promote cellular transformation to generate malignant cells. In a recently published article in Nature Medicine, a molecular characterization of tumor tissue and circulating tumor DNA (cDNA) from non-selected patients with metastatic gastric… More >

View

1135

Download

962